The intravenous antibiotic Cubicin has been suspected by the Food and Drug Administration, which has cautioned the physicians against the use of the said drug that can pose risk of deadly disease eosinophilic pneumonia. Cubist Pharmaceuticals is the manufacturer of Cubicin.

Since 2004, seven cases of getting affected by eosinophilic pneumonia have been reported and the identification of the disease was based on the review of the medical literature and unfavorable incident reports. The disease infects the body by amassing a kind of white blood cells called eosinophils in the lungs. It exhibits symptoms like fever, cough, complexity breathing and shortness of breathing.

If the ailment is not detected timely, it can lead to deadly results.

The FDA approved the generic drug daptomycin branded by the name Cubicin in 2003 to treat skin ailments like staphylococcus aureus bacteremia. In 2006, it got the sanction for the treatment of bloodstream infections.

The FDA is suggesting the Company to put a warning label on the Cubicin. A similar move was taken in 2007 when label was altered to warn the users of its ill-effects.

The agency released a statement in a Drug Safety Communication expressing that the Company should depict the connection of eosinophilic pneumonia and Cubicin in its warnings, precautions and marketing activities.